The Latest on the NASCAR race at Dover International Speedway (all times local):
5:55 p.m.
Kyle Larson pulled away late and won the playoff race at Dover International Speedway to snap a 75-race winless streak and earn an automatic berth in the next round.
Joey Logano (22) pits during the Drydene 400 NASCAR Cup Series playoff auto race, Sunday, Oct. 6, 2019, at Dover International Speedway in Dover, Del. (AP PhotoJason Minto)
Larson had nine runner-up finshes in the No. 42 Chevrolet since his last win Sept. 9, 2017, in Richmond, keeping the Chip Ganassi Racing driver in championship contention.
Larson has six career Cup victories and his first one in the playoffs. He led 154 laps late after Denny Hamlin went from dominant to dud midway through the race. Hamlin led 219 laps before fading.
Larson did win the non-points All-Star race this year.
NASCAR playoff drivers took the top six spots: Martin Truex Jr. finished second, followed by Alex Bowman, Kevin Harvick, Hamlin and Kyle Busch.
4:40 p.m.
Denny Hamlin led 219 laps but faded at the end of the second stage to allow Martin Truex Jr. to zip by him and win the stage at Dover.
Truex, Kyle Larson and Hamlin took the top three spots as the stage in the NASCAR playoff ended.
Hamlin led most of the race from the pole as he chased his first win at Dover in a career that started in 2006. He is making his 500th career start and Dover is celebrating its 100th race.
3:45 p.m.
Pole sitter Denny Hamlin has won the first stage of the NASCAR race at Dover. Playoff drivers Martin Truex Jr. and Kyle Larson followed Hamlin.
Hamlin is trying to win at Dover for the first time in 28 races.
Joey Logano and Chase Elliott had their races ruined with major issues with their cars inside 10 laps.
3 p.m.
Reigning series NASCAR Cup champion Joey Logano and Chase Elliott both ran into major issues in their playoff push early at Dover International Speedway.
Logano's No. 22 Ford had an issue with the rear of the car and was forced to the garage before the green flag dropped. Elliott, who won last week at Charlotte, also had his Chevrolet sent to the garage before 10 laps were complete with a blown engine.
Both drivers are among the 12 in the NASCAR playoff field. Dover was the first race of the second round.
2:45 p.m.
Denny Hamlin is on the pole as he goes for his first victory at Dover International Speedway.
Hamlin is for 0 for 27 in races on the concrete mile track dating to 2006. He has only four top-five finishes, did not finish four times and his average finish is just 17.5 place. He finished 21st in the No. 11 Toyota in the May race at Dover.
Martin Truex Jr. won the spring race.
Hamlin will lead the field to green for the second round of the playoffs in his 500th career NASCAR Cup Series start. Richard Petty at Trenton in 1970 and Matt Kenseth at New Hampshire in 2013 are the only drivers to win their 500th start.
Joe Gibbs Racing has 15 wins this season and needs three more in seven races to match Hendrick Motorsports' record total of 18 in 2007.
More AP auto racing: https://apnews.com/apf-AutoRacing and https://twitter.com/AP_Sports
PORTSMOUTH, N.H.--(BUSINESS WIRE)--May 2, 2024--
Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523), and NovaScan, Inc., a company that develops breakthrough technology for cancer detection and stratification, announce that they have signed a letter of intent for a U.S. exclusive commercial distribution agreement for MarginScan™, a medical device that will support physicians in real-time detection of non-melanoma skin cancer. Epredia has engaged Avantik, a company specializing in supporting diagnostic labs with their operations, with getting this new device into the hands of Mohs surgeons.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502185446/en/
Skin cancer is the most common group of cancers diagnosed worldwide 1, and it is estimated that one in five Americans will develop skin cancer in their lifetime 2. Non-melanoma skin cancers (NMSC) are the most common cancers in the United States, affecting more than 3 million Americans a year 3. More than 20 percent of Americans are expected to develop NMSC before reaching age 70. Most surgeries for NMSC are simple excisions, which may result in removal of substantial healthy tissue around the suspected cancer.
MarginScan™ is designed to address this challenge by supporting Mohs surgery procedures for skin cancer treatment. Mohs Micrographic Surgery (MMS) is an operative method used to detect the presence or absence of a tumor in the margins of a surgical excision. In an MMS procedure, cancer tissue is excised in stages, then flash-frozen and assessed histologically in an onsite lab until clean margins are obtained. Previously, MMS was the only modality for skin cancer treatment that involved comprehensive margin assessment during a procedure. MarginScan™ is designed to use an electrical assessment to confirm cancer-free margins without the intraoperative histological assessment. This has the potential to allow for faster excisions that spare more healthy tissue, leading to improved outcomes for both patients and clinicians.
With this planned agreement, Epredia will serve as the primary distribution partner of MarginScan™ and will have exclusive distribution rights in the United States. Along with distribution, Epredia will be responsible for all marketing and commercial activities related to the launch and sale of MarginScan™. Epredia will work closely with Avantik to market and sell the new device to Mohs surgeons.
MarginScan™ will be the latest addition to Epredia’s world-class portfolio of precision cancer diagnostics products and services that provide a seamless end-to-end laboratory workflow, including slide scanners and printers, cryostats, tissue processors, and consumables such as slides and reagents. In addition to offering MarginScan™, Epredia will also provide consumable products that are used with the device, such as the MarginScan™ electrode and proprietary electrolytic gel used during excisions.
The two companies anticipate a 2025 U.S. launch for MarginScan™. This distribution agreement builds on a previous partnership between NovaScan and PHC Corporation, another subsidiary of PHC Holdings Corporation that is focused on the development and manufacturing of innovative medical testing devices. PHC Holdings Corporation is referred to collectively with its subsidiaries as PHC Group.
Steven Lynum, President of Epredia, said, “With more than 85 years supporting precision cancer diagnostics, we strive to continuously serve the changing needs of our customers by working with innovative companies like NovaScan to deliver the best solutions. Helping providers make faster, more accurate diagnoses and ultimately improving patient care is what makes this initiative so important.”
Craig Davis, CEO of NovaScan, remarked, “NovaScan is thrilled to be partnering with Epredia to bring MarginScan™ to clinical healthcare providers in the U.S. We are proud for MarginScan™ to join Epredia’s portfolio of market-leading cancer diagnostics products. We believe that MarginScan™ will play an important role in skin cancer detection and treatment.”
Mark Zacur, CEO of Avantik, added, “Our team is continually sourcing the best solutions to expand our portfolio of solutions supporting Mohs clinics with their critical work. We are honored that Epredia selected Avantik as their partner to bring this breakthrough device to our network of providers and their patients.”
About Epredia
Epredia is a global leader in the anatomical pathology field, providing comprehensive solutions for precision cancer diagnostics and tissue diagnostics. Powered by key brands, including Erie Scientific, Menzel-Gläser, Microm, Shandon, and Richard-Allan Scientific, Epredia’s portfolio includes microscope slides, instruments and consumables. Epredia was established following the acquisition of Thermo Fisher Scientific’s Anatomical Pathology business by PHC Holdings in 2019. Epredia has operations in major sites in the United States, the United Kingdom, Germany, Switzerland and China with a total of around 1,200 employees. Epredia is committed to achieving its mission to improve lives by enhancing cancer diagnostics for patients around the world. For further information on Epredia and its products, please visit www.epredia.com.
About PHC Holdings Corporation (PHC Group)
PHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Epredia, Ascensia Diabetes Care, LSI Medience Corporation, Mediford, and Wemex. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s consolidated net sales in FY2022 were JPY 356.4 billion with global distribution of products and services in more than 125 countries and regions. www.phchd.com
About NovaScan
About NovaScan: Based in Chicago, NovaScan ( www.novascaninc.com ) is a clinical stage oncology diagnostic and stratification company that has developed a low cost, point of care platform for real time cancer detection and stratification. NovaScan’s platform is active in skin, GI, lung and breast.
About Avantik
Founded in 1971, Avantik specializes in supporting diagnostic laboratories with maintaining their critical operations. The company offers a national network of more than 250 engineers, technicians and service personnel that assist diagnostic labs with increasing their productivity, enhancing their products and streamlining their processes. It also manages a comprehensive inventory of high-quality lab equipment and consumables that it continually expands to provide labs with new products that advance their goals for fast and accurate diagnoses. In 2023, Avantik partnered with Water Street Healthcare Partners, an investment firm dedicated to building market leaders in health care, to advance its goals for expansion and building on its legacy as a trusted partner to diagnostic laboratories. To learn more about Avantik, visit www.avantik-us.com.
1 Source: World Health Organization.
2 Source: World Health Organization.
3 Source: American Academy of Dermatology.
MarginScan™ Device for Non-Melanoma Skin Cancer Detection (Photo: Business Wire)
